Low expression of microRNA‐340 confers adverse clinical outcome in patients with acute myeloid leukemia

• Published in: Journal of cellular physiology Vol. 234; no. 4; pp. 4200 - 4205
• Main Authors: Wang, Qi, Feng, Tao, Xu, Jun, Miao, Mei‐Hua, Ji, Xue‐Qiang, Zhu, Hong, Shao, Xue‐Jun
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2019
• Subjects: Acute myeloid leukemia; Acute promyeloid leukemia; Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor - genetics; Bone marrow; Cancer; Case-Control Studies; Cell proliferation; Clinical outcomes; Down-Regulation; Drug resistance; expression; Female; Health risk assessment; Humans; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - therapy; Male; Medical prognosis; MicroRNAs; MicroRNAs - genetics; microRNA‐340; Middle Aged; miRNA; Myeloid leukemia; Patients; Polymerase chain reaction; prognosis; Promyeloid leukemia; Regression analysis; Remission; Remission Induction; Ribonucleic acid; Risk analysis; Risk factors; RNA; Survival; Time Factors; Treatment Outcome; Tumor suppressor genes; Young Adult; expression; acute myeloid leukemia; prognosis; microRNA-340

MicroRNA‐340 (miR‐340) was considered as a tumor suppressor by affecting cancer cell proliferation, apoptosis, invasion, and migration, and was downregulated in diverse cancers. Moreover, dysregulation of miR‐340 was also found to be associated with drug resistance and predicted patients’ survival i...